In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 1176 for your search:

Drug:  carboplatin
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer

Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MC#08-002, IIT 12230, NCT00883675

A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12628, H3E-JE-JMII, NCT01020786

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 4 to 70
Sponsor: Other
Protocol IDs: CDR0000066968, RP 98-15, RPCI-RP-9815, NCI-V99-1527, NCT00003816

Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000067047, SPRI-C/I98-102, SPRI-C98-102, NCI-V99-1544, NCT00003880

Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000068525, EORTC-GU-30986, NCT00014274

Phase II/III Chemotherapy with MVP (MITO/VBL/CACP) vs CHIP vs CBDCA vs VBL/CACP vs MVP-CAMP (MITO/VBL/CACP/CTX/ADR/MTX/PCB) in Patients with Metastatic (Stage III) non-Small Cell Bronchogenic Carcinoma

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: no age specified
Sponsor: NCI
Protocol IDs: EST-1583

Phase II/III Comparison of the Platinum Compounds CBDCA vs CHIP vs CACP for Recurrent or Metastatic Epidermoid Carcinoma of the Head and Neck

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: UMCC-8223

Phase III Master Protocol for Randomized Comparison of Single-agent Chemotherapy vs Standard Therapy with CAF (CTX/DOX/5-FU) in Previously Untreated Patients with Stage IV Breast Carcinoma --- Amonafide and Other Phase II Agents

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 16 to physiologic 70
Sponsor: NCI
Protocol IDs: CLB-8642, CALGB-8642

Phase II Evaluation of IPP, CBDCA, CHIP, and epi-ADR as Single Agents Prior to Phase III Randomized Comparison of CECA (CACP/VP-16/CTX/ADR) vs High-Dose CACP/VP-16/CTX/ADR in Children Aged at Least 365 Days with Previously Untreated Stage D Neuroblastoma and Phase III Multimodal Treatment of Stage C Disease

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 1 to 21
Sponsor: NCI
Protocol IDs: POG-8741/42, POG-8741, POG-8742

10.

Phase II/III Randomized Comparison of Consolidation with Intensive Chemotherapy Using CDDP/VP-16/DOX/IFF vs Myeloablative Chemoradiotherapy and Autologous Marrow Rescue and of Continuation Therapy with Isotretinoin vs No Further Therapy in High-Risk Neuroblastoma

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 0 to 18
Sponsor: NCI
Protocol IDs: CCG-3891

11.

Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 40 to 75
Sponsor: Other
Protocol IDs: Hamamatsu 18-66, NCT00752115

12.

Paclitaxel and Carboplatin With or Without BMS-275291 in Treating Patients With Advanced or Metastatic Non-small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: BR18, CAN-NCIC-BR18, BMS-CA161-003, CDR0000068153, NCT00006229

13.

Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: BR24, CAN-NCIC-BR24, ZENECA-CAN-NCIC-BR24, FHCRC-6107, UWCC-UW 6107, UWCC- 06-2707-H/B, CDR0000450850, NCT00245154

14.

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068744, E4599, CALGB-E4599, ECOG-4599, NCT00021060

15.

An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-001346-41, ISRCTN68510403, NCT00532194

16.

Phase III Randomized Study of G-CSF Priming Prior to Neoadjuvant TAX/CBDCA Followed by a Phase I Dose-Seeking Study of TAX/CBDCA During Definitive Radical Thoracic Irradiation for Stages IIIB/Bulky IIIA Nonsmall Cell Lung Cancer (Summary Last Modified 12/95)

Phase: Phase III, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: FCCC-94001, NCI-V94-0479

17.

Phase III Randomized Comparison of Combination Chemotherapy with CBDCA/CTX vs CACP/CTX in Patients with Stage III/IV Ovarian Carcinoma

Phase: Phase III, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-8412

18.

Phase III Randomized Study of PIXY321 vs GM-CSF for Mobilization of Hematopoietic Progenitors in Women with Metastatic Breast Carcinoma (Summary Last Modified 03/97)

Phase: Phase III
Type: Treatment
Status: Completed
Age: no greater than 60
Sponsor: NCI
Protocol IDs: NU-93B1, NCI-T93-0058D, T93-0058

19.

Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors

Phase: Phase III
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: Other
Protocol IDs: CDR0000063579, FRE-IT94, FRE-FNCLCC-IT94, NCI-F94-0019, NCT00002566

20.

Phase III Randomized Study of TAX/CDDP vs CTX/CDDP in Patients with Advanced Epithelial Ovarian Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: EORTC-55931, CAN-NCIC-OV10, SCOTTISH-GYN-G42, SGCSG-NOCOVA-9410, OV10

21.

Phase III Randomized Study of Bleomycin, Etoposide, and Cisplatin (BEP) With or Without High-Dose Carboplatin, Etoposide, and Cyclophosphamide Plus Autologous Bone Marrow or Peripheral Blood Stem Cell Transplantation in Male Patients With Previously Untreated Poor- or Intermediate-Risk Germ Cell Tumors

Phase: Phase III
Type: Treatment
Status: Completed
Age: 12 and over
Sponsor: NCI
Protocol IDs: MSKCC-94076, CLB-99812, E-3894, SWOG-9442, NCI-T94-0086D, NCT00002596, T94-0086

22.

Phase III Randomized Study of PIXY321 Both Before and After vs Only After ICE (IFF/CBDCA/VP-16) to Ameliorate Myelotoxicity in Patients with Previously Untreated Malignancies (Summary Last Modified 03/96)

Phase: Phase III
Type: Treatment
Status: Closed
Age: over 18
Sponsor: Other
Protocol IDs: YALE-HIC-7653, NCI-V94-0553

23.

Phase III Study of Multimodality Therapy Based on Prior Therapy and Histology in Patients With Relapsed Wilms' Tumor

Phase: Phase III
Type: Treatment
Status: Completed
Age: 21 and under at diagnosis
Sponsor: NCI
Protocol IDs: COG-Q9402, NWTS-Q9402, CCG-4942, POG-9444, INT-0152, NWTS-5/R, NCT00002610, Q9402

24.

Phase III Randomized Study of Platinum Compound and Paclitaxel in Optimal Stage III Ovarian Epithelial Cancer: Cisplatin and Paclitaxel (24-Hour Continuous Infusion) vs Carboplatin and Paclitaxel (3-Hour Infusion)